ClinicalTrials.gg
Status unknownNCT02922166Updated Jun 10, 2019

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

A Phase 1 interventional study of SRX246 and Placebo in Fear and Anxiety, sponsored by Azevan Pharmaceuticals. Status unknown at 1 site in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-10.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Azevan Pharmaceuticals · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.

Read the detailed description

The study will use a double-blind, cross-over design in which each subject will receive placebo and SRX246 for 5-7 days before testing (given in counter-balanced order). The study will examine the effect of the drug on the potentiation of startle using a well-established paradigm that involves anticipation of no-shock, predictable shock, and unpredictable shock. Drug effects on emotion recognition will also be explored.

02

Conditions studied

  • Fear
  • Anxiety

Browse trials for

03

In context

Anxiety Disorders Unverified

7,220 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's enrollment of 36 is below the median of 80 across 6,071 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Azevan Pharmaceuticals is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers, ages 21-50, inclusive.
  • Subjects able to give their consent and have signed forms indicating that they understand the purpose and procedures of the study and are willing to participate in the study procedures and restrictions.
  • (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).

Exclusion criteria

Exclusion Criteria:

  • Non-English speakers
  • Current or history of Axis I psychiatric disorder(s) as identified with the Structured Clinical Interview for , non-patient edition (SCID-np) and clinical evaluation.
  • Active or history of active suicidal ideation.
  • Lifetime alcohol or drug dependence according to the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np).
  • All prescription and non-prescription medications and herbal remedies are prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication and until at least 7 days or 5 half-lives (whichever is longer) after last dose of study medication, except hormonal in females.
  • Clear evidence of a first-degree relative with history of psychosis, bipolar disorder or major depression as determined by the family history method; specifically, participant will know diagnosis or treatment in order to confirm presence of disorder.
  • Subject is currently participating in another clinical trial in which (s)he is or will be exposed to an or non-investigational drug or device, or has done so within the preceding month.
  • Current evidence or history of significant medical illness or organic brain impairment, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), diabetes insipidus (DI), stroke, epilepsy, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment that would likely interfere with the action, absorption, distribution, metabolism, or excretion of SRX246, or influence psychophysiological responses.
  • Current evidence of median nerve entrapment or carpal tunnel syndrome.
  • Any laboratory abnormality that in the investigators' judgment is considered to be (, TSH, LFT, etc.).
  • Abnormal urine specific gravity (below 1.00 or above 1.03) as documented by urine sample refractometry.
  • Subject who has resting blood pressure outside of a systolic blood pressure range of 90-140 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements taken up to 10 minutes apart.
  • Subject who has resting pulse rate greater than 100 bpm or less than 50 bpm on two consecutive measurements taken up to 10 minutes apart.
  • Consumption of illicit substances or positive urine toxicology screen throughout the study.
  • Pregnancy, lactating/breastfeeding, or positive pregnancy test.
  • A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected to SRX246, or allergy to gelatin.
  • Lack of measurable startle response (3 times the baseline EMG activity) for all 9 startles used during the habituation visit.
  • Subjects who would be noncompliant with the visit schedule or study procedures. Possible noncompliance may include planned vacations or planned hospitalizations during the study.
  • For women who are able to get pregnant and men who are able to father a child, unwillingness to use at least two effective birth control methods for 15 days prior to the time they enroll in the study, and for 15 days after their last exposure to the study drug. Effective methods of contraception for this study include:

    1. hormonal contraception (birth control pills, injected hormones or vaginal ring),
    2. intrauterine device,
    3. barrier methods (condom or diaphragm) combined with spermicide, and
    4. surgical sterilization (hysterectomy, tubal ligation, or vasectomy).
  • Employee of NIMH or an immediate family member who is a NIMH employee
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    SRX246

    SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days

    Drug: SRX246

  • Placebo comparator
    Placebo

    Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days

    Drug: Placebo

Interventions

  • DrugSRX246

    oral capsule

  • DrugPlacebo

    oral capsule

06

What researchers measure

Primary outcomes

  1. Change in startle reflex between SRX246 and Placebo

    Subjects will be exposed to none (N), predictable (P) and unpredictable (U) acoustic and electric shocks.

    Time frame: up to 7 days

Secondary outcomes

  1. Change in emotional expression recognition between SRX246 and Placebo

    Subjects will be shown pictures of faces exhibiting anger, disgust, fear, happiness, sadness and surprise.

    Time frame: up to 7 days

  2. Change in State Anxiety Scale between SRX246 and Placebo

    Subjects will rate their anxiety level during assessments using a self-administered rating scale.

    Time frame: up to 7 days

07

Study locations

1 site
  • National Institute of Mental Health
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data and samples will be shared with Azevan Pharmaceuticals Inc., its affiliates and research partners working with Azevan Pharmaceuticals Inc.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2019, 27 months.

Of 71 phase 1 interventional studies under Anxiety Disorders, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2016
First posted
Oct 4, 2016
StartActual
Feb 3, 2017
Primary completionActual
May 10, 2019
CompletionEst.
Dec 2019
Last update
Jun 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02922166
Lead sponsor
Azevan Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Feb 3, 2017
Primary completion
May 10, 2019
Completion
Dec 2019 (estimated)
Last update
Jun 10, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRX246

Start the discussion